Pulmonary Arterial Hypertension Market by Drug Class (Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, Phosphodiesterase-5 (PDE-5) Inhibitors, and Soluble Guanylate Cyclase (sGC) Stimulators); By Application (Hospitals, Clinics, and Others); By Geography (North America, Asia-Pacific, Europe, South America, and RoW), Industry Trends, Estimation & Forecast, 2018 – 2026

Market Overview

The Global Pulmonary Arterial Hypertension market is expected to reach approximately $8.4 billion by 2026, with a projected CAGR of 4.7% during the forecast period. Pulmonary arterial hypertension is a progressive disorder in which blood pressure rises in the pulmonary artery, vein, or capillaries that may lead to shortness of breath, dizziness, and fainting among others.

Market Dynamics

Increasing prevalence of PAH disorder owing to rising risk factors such as sedentary lifestyle, consumption of tobacco and alcohol, smoking, and other idiopathic conditions propels the growth of the global pulmonary arterial hypertension market. Various breakthrough therapies for treatment of pulmonary arterial hypertension, government support for the development of orphan drugs, and increasing geriatric population are other major growth stimulants for the Europe carpet market. However, expiry of patents of major pulmonary arterial drugs such as Letiaris, Tyvaso, Tracleer, and Adcirca may hamper the market from growing. Moreover, Favorable policies by government is likely to gain significant impetus for the pulmonary arterial hypertension market share in the coming years.

Market Segmentation

The study provides a crucial view of the pulmonary arterial hypertension by segmenting the market based on the drug class, application, and geography. By drug class segment, the segmentation comprises of endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators. Hospitals, clinics, and others are the classification of the application segment. Furthermore, geographical coverage has been offered for each of the major regions including North America, Asia-Pacific, Europe, Row, and South America.

Scope of the Global Pulmonary Arterial Hypertension Market

By Drug Class

• Endothelin Receptor Antagonists (ERAs)
• Prostacyclin and Prostacyclin Analogs
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators

By Application

• Hospitals
• Clinics
• Other Applications

By Geography

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Korea
  • Rest of APAC
• South America
  • Brazil
  • Rest of South America
• Rest of the World
  • Middle East
  • Africa

TABLE OF CONTENTS

Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Market Scope

Chapter 2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources

Chapter 3 Market Overview
3.1 Report Segmentation & Scope
3.2 Key Market Trends
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Porter’s Five Forces Analysis
3.4 Market Share Analysis

Chapter 4 Global Pulmonary Arterial Hypertension Market by Drug Class: Market Size and Forecast, 2018 – 2026
4.1 Introduction
4.1.1 Market Size and Forecast
4.2 Endothelin Receptor Antagonists (ERAs)
4.2.1 Market Size and Forecast
4.3 Prostacyclin and Prostacyclin Analogs
4.3.1 Market Size and Forecast
4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
4.4.1 Market Size and Forecast
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
4.5.1 Market Size and Forecast

Chapter 5 Global Pulmonary Arterial Hypertension Market by Application: Market Size and Forecast, 2018 – 2026
5.1 Introduction
5.1.1 Market Size and Forecast
5.2 Hospitals
5.2.1 Market Size and Forecast
5.3 Clinics
5.3.1 Market Size and Forecast
5.4 Other Applications
5.4.1 Market Size and Forecast

Chapter 6 Global Pulmonary Arterial Hypertension Market by Geography: Market Size and Forecast, 2018 – 2026
6.1 Introduction
6.1.1 Market Size and Forecast
6.2 North America
6.2.1 North America Market Size & Forecast, By Country
6.2.2 North America Market Size & Forecast, By Drug Class
6.2.3 North America Market Size & Forecast, By Application
6.2.4 The U.S.
6.2.4.1 Market Size and Forecast
6.2.5 Canada
6.2.5.1 Market Size and Forecast
6.2.6 Mexico
6.2.6.1 Market Size and Forecast
6.3 Europe
6.3.1 Europe Market Size and Forecast, By Country
6.3.2 Europe Market Size and Forecast, By Drug Class
6.3.3 Europe Market Size and Forecast, By Application
6.3.4 UK
6.3.4.1 Market Size and Forecast
6.3.5 Germany
6.3.5.1 Market Size and Forecast
6.3.6 France
6.3.6.1 Market Size and Forecast
6.3.7 Italy
6.3.7.1 Market Size and Forecast
6.3.8 Spain
6.3.8.1 Market Size and Forecast
6.3.9 Rest of Europe
6.3.9.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Asia-Pacific Market Size and Forecast, By Country
6.4.2 Asia-Pacific Market Size and Forecast, By Drug Class
6.4.3 Asia-Pacific Market Size and Forecast, By Application
6.4.4 India
6.4.4.1 Market Size and Forecast
6.4.5 China
6.4.5.1 Market Size and Forecast
6.4.6 Australia
6.4.6.1 Market Size and Forecast
6.4.7 Japan
6.4.7.1 Market Size and Forecast
6.4.8 South Korea
6.4.8.1 Market Size and Forecast
6.4.9 Rest of Asia-Pacific
6.4.9.1 Market Size and Forecast
6.5 South America
6.5.1 South America Market Size and Forecast, By Country
6.5.2 South America Market Size and Forecast, By Drug Class
6.5.3 South America Market Size and Forecast, By Application
6.5.4 Brazil
6.5.4.1 Market Size and Forecast
6.5.5 Rest of South America
6.5.5.1 Market Size and Forecast
6.6 RoW
6.6.1 RoW Market Size and Forecast, By Country
6.6.2 RoW Market Size and Forecast, By Drug Class
6.6.3 RoW Market Size and Forecast, By Application
6.6.4 RoW Market Size and Forecast, By End-User
6.6.5 Middle East
6.6.5.1 Market Size and Forecast
6.6.6 Africa
6.6.6.1 Market Size and Forecast

Chapter 7 Company Profiles
7.1 Actelion Pharmaceuticals, Ltd.
7.2 Bayer HealthCare
7.3 Gilead Sciences, Inc.
7.4 GlaxoSmithKline Plc.
7.5 Novartis International AG
7.6 Pfizer, Inc.
7.7 United Therapeutics Corporation

Pulmonary Arterial Hypertension Market Key Players

• Actelion Pharmaceuticals, Ltd.
• Bayer HealthCare
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc.
• Novartis International AG
• Pfizer, Inc.
• United Therapeutics Corporation